Anthropic makes its Nasdaq debut at $111.50 per share after pricing at $83 each, giving it a ~$2T market cap, in a historic moment for the AI industry (Reuters)
Anthropic has officially entered public markets with an initial trading price that substantially exceeded its expectations. The company had initially priced its shares at $83.00 each ahead of the listing before opening at $111.50 per share on the Nasdaq. At this opening level, the artificial intelligence firm is valued at roughly $2 trillion. This debut stands as a historic milestone for the entire AI industry.
Key points
The successful public listing establishes a historic valuation benchmark for the artifici…: The successful public listing establishes a historic valuation benchmark for the artificial intelligence sector.
Public market trading began significantly higher than the initial pricing set ahead of th…: Public market trading began significantly higher than the initial pricing set ahead of the market debut.
Anthropic achieved an approximate $2 trillion market valuation upon officially opening on…: Anthropic achieved an approximate $2 trillion market valuation upon officially opening on the Nasdaq.
Sources checked by our analysis pipeline: 1
CNBC: |
Reuters: |
New York Times: |
Jasmine Sun / New York Times: |
Koray Kavukcuoglu / Google: |
Abner Li / 9to5Google: |
Emma Roth / The Verge: |
Financial Times: |
The Information: |
Tim Bradshaw / Financial Times: |
Bill Toulas / BleepingComputer: |
Will Mathis / Bloomberg: |
Gerardo Fortuna / Politico: |
OpenAI: |
OpenAI: |
Jaspreet Singh / Reuters: |
New York Times: |
Todd Spangler / Variety: |
Jay Peters / The Verge: |
Joseph Bernstein / New York Times: |
Lynn Doan / Bloomberg: |
Aisha Malik / TechCrunch: |
Teresa Xie / Bloomberg: |
Yuan Gao / Bloomberg: |
Bloomberg: |
Dean Ball / OpenAI: |
Dana Goldstein / New York Times: |
Saritha Rai / Bloomberg: |
Christian Davies / Financial Times: |
New York Times: |
CoinDesk: |
Elena Eisenstadt / Bloomberg: |
This is a Techmeme archive page. It shows how the site appeared at 11:56 AM ET, November 19, 2026.
The most current version of the site as always is available at our home page. To…
Investors are continuing to direct significant capital toward computational biology platforms aimed at shortening pharmaceutical research timelines. By securing major venture backing, the biotechnology firm gains substantial resources to advance algorithms that streamline the identification of therapeutic candidates. The rapid progression in its capital structure reflects strong market confidence in software-driven approaches to laboratory science.
Domestic pharmaceutical innovation is turning toward advanced artificial intelligence while federal leaders focus on strategic global positioning against international competitors. Merck is deploying external machine learning tools to accelerate cancer therapies, even as key leadership transitions create regulatory uncertainty. The evolving intersection of cutting-edge technology and government oversight will determine the pace of modern drug development.
The London High Court defence tests whether artificial intelligence developers are responsible for the misuse and training architecture of their platforms. Legal representatives contend that obviously fictitious media does not infringe privacy rights, while the claimant argues designers cannot hide behind user prompts. The outcome could establish vital accountability standards as global regulators intensify scrutiny over non-consensual synthetic material.